ADCs in NSCLC Post-ELCC
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Released: May 18, 2021

Expiration: May 17, 2022

David Planchard
David Planchard, MD, PhD
Egbert F. Smit
Egbert F. Smit, MD, PhD
Helena Yu
Helena Yu, MD

Activity

Progress
1
Course Completed

In this episode, Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and  Helena A. Yu, MD, answer audience questions from a live webinar regarding clinical data on antibody–drug conjugates in NSCLC including:

  • Biopsies and biomarker testing considerations
  • Tumor heterogeneity and targeting of brain metastases
  • Liquid biopsies
  • Sequencing of ADCs following previous therapy
  • Toxicity management

Presenters:

Egbert F. Smit, MD, PhD
Professor
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands
Department of Thoracic Oncology
Netherlands Cancer Institute
Amsterdam, Netherlands

David Planchard, MD, PhD
Head of Thoracic Group
Department of Medical Oncology
Institute Gustave Roussy
Villejuif, France

Helena A. Yu, MD
Assistant Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York